Clinical features of opticospinal multiple sclerosis with anti-aquaporin 4 antibody

European Neurology

Volumn 60, Issue 1, 2008, Pages 37-42

  Kanzaki, Mami ^a   Mochizuki, Hitoshi ^b   Ogawa, Go ^a   Tanaka, Keiko ^c   Araki, Manabu ^a   Motoyoshi, Kazuo ^a   Hammond Tooke, Graeme ^d   Kamakura, Keiko ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Higashisaitama National Hospital   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Anti aquaporin 4 antibody; Neuromyelitis optica; Opticospinal multiple sclerosis; Somatosensory evoked potential; Syrinx formation

Indexed keywords

AQUAPORIN 4; INTERFERON BETA SERINE;

ADULT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; EVOKED SOMATOSENSORY RESPONSE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CONTENT;

ADULT; ANTIGEN-PRESENTING CELLS; AQUAPORIN 4; AUTOANTIBODIES; BRAIN; ELECTROPHYSIOLOGY; FEMALE; HUMANS; IMMUNOTHERAPY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREVALENCE; SPINAL CORD;

EID: 44849134908     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127978     Document Type: Article

References (26)

1. Kira J: Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-127.
2. Houzen H, Niino M, Kikuchi S, et al: The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 2003;211:49-53.
3. Itoh T, Aizawa H, Hashimoto K, et al: Prevalence of multiple sclerosis in Asahikawa, a city in northern Japan. J Neurol Sci 2003;214:7-9.
4. Kira J, Yamasaki K, Horiuchi I, et al: Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan. J Neurol Sci 1999;166:53-57.
5. Kira J, Kanai T, Nishimura Y, et al: Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 1996;40:569-574.
6. Misu T, Fujihara K, Nakashima I, et al: Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002;125:2460-2468.
7. Lucchinetti CF, Mandler RN, McGavern D, et al: A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-1461.
8. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG: The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114.
9. Lennon VA, Wingerchuk DM, Kryzer TJ, et al: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112.
10. Lennon VA, Kryzer TJ, Pittock SJ, et al: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-477.
11. Misu T, Fujihara K, Kakita A, et al: Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130:1224-1234.
12. Roemer SF, Parisi JE, Lennon VA, et al: Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130:1194-1205.
13. Sinclair C, Kirk J, Herron B, Fitzgerald U, McQuaid S: Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol 2007;113:187-194.
14. Takahashi T, Fujihara K, Nakashima I, et al: Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-1243.
15. Tanaka K, Tani T, Tanaka M, et al: Antiaquaporin 4 antibody in Japanese multiple sclerosis with long spinal cord lesions. Mult Scler 2007;13:850-855.
16. Matsuoka T, Matsushita T, Kawano Y, et al: Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007;130:1206-1223.
17. Poser CM, Paty DW, Scheinberg L, et al: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
18. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
19. Yamasaki K, Horiuchi I, Minohara M, et al: HLA-DPB1 *0501- associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain 1999;122:1689-1696.
20. Aminoff MJ, Davis SL, Panitch HS: Serial evoked potential studies in patients with definite multiple sclerosis. Clinical relevance. Arch Neurol 1984;41:1197-1202.
21. Wingerchuk DM, Lennon VA, Pittock SJ, et al: Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.
22. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG: Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390-396.
23. McDonald WI, Compston A, Edan G, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
24. Kwee IL, Nakada T: Syrinx formation in multiple sclerosis. Br J Radiol 1985;58:1206-1208.
25. Li KC, Chui MC: Conventional and CT metrizamide myelography in Arnold-Chiari I malformation and syringomyelia. Am J Neuroradiol 1987;8:11-17.
26. Sherman JL, Barkovich AJ, Citrin CM: The MR appearance of syringomyelia: new observations. Am J Roentgenol 1987;148:381-391.